Stage 3 ovarian cancer means the cancer has spread beyond the ovaries and pelvis into the abdominal lining (the peritoneum) or to nearby lymph nodes. It is the most commonly diagnosed stage of ovarian cancer, largely because the disease produces few obvious symptoms early on. The five-year relative survival rate ranges from about 31% to 71% depending on how far the cancer has spread, but treatment has improved significantly in recent years, particularly for women whose tumors carry certain genetic mutations.
How Stage 3 Is Classified
Stage 3 is divided into substages based on exactly where and how much cancer is found outside the pelvis. The distinctions matter because they influence treatment planning and expected outcomes.
Stage 3A1: Cancer has spread only to the retroperitoneal lymph nodes (the nodes that sit along the back wall of the abdomen). This substage is further split by size: 3A1(i) means the lymph node deposits are smaller than 10 mm, and 3A1(ii) means they are 10 mm or larger.
Stage 3A2: Microscopic cancer deposits are found on the abdominal lining outside the pelvis, with or without lymph node involvement. At this point the spread is too small to see with the naked eye during surgery and is only confirmed under a microscope.
Stage 3B: Visible tumor deposits up to 2 cm are present on the abdominal lining, with or without lymph node spread.
Stage 3C: Tumor deposits larger than 2 cm are found on the abdominal lining, including the surface of the liver or spleen. This is the most common substage at diagnosis.
Symptoms at This Stage
By stage 3, most women experience noticeable symptoms, though they often overlap with common digestive complaints, which is one reason diagnosis is frequently delayed. Persistent bloating, a feeling of fullness after eating very little, and abdominal or pelvic pain are the hallmarks. Many women also report a loss of appetite, ongoing indigestion, constipation, and nausea.
A hallmark of advanced ovarian cancer is fluid buildup in the abdomen, known as ascites. This happens when cancer cells irritate the abdominal lining, causing it to leak fluid. Ascites can make the belly visibly swollen, cause discomfort, and press on the diaphragm enough to cause shortness of breath. In some cases, the growing cancer can partially or completely block the bowel, leading to severe bloating, vomiting, and inability to pass stool. It can also press on the tubes that drain urine from the kidneys, potentially causing kidney swelling and damage if not addressed.
How Stage 3 Is Diagnosed
Contrast-enhanced CT scanning is the gold standard for staging ovarian cancer. It allows doctors to evaluate the tumor’s relationship to surrounding organs and identify cancer deposits on the abdominal lining and in lymph nodes, with a reported staging accuracy of up to 94%. CT is also used to calculate a peritoneal cancer index, a scoring system that helps predict whether surgery can successfully remove all visible disease. The main limitation is that CT struggles to detect peritoneal implants smaller than 1 cm.
MRI, particularly with diffusion-weighted imaging, is better at picking up those small peritoneal deposits and is sometimes used as a complement to CT when surgical planning requires more detail. PET/CT is not routinely used for initial staging because it has limited sensitivity for small implants and can produce false positives from inflammatory conditions, but it plays a role in certain unclear cases or when recurrence is suspected.
A blood marker called CA-125 is frequently elevated in ovarian cancer and is used throughout the process. While it is not reliable enough on its own to diagnose cancer (other conditions can raise it too), it serves as a useful baseline. Once treatment begins, a falling CA-125 level generally signals the cancer is responding. After treatment ends, periodic CA-125 checks help detect recurrence early, since rising levels can indicate the cancer has returned.
Surgery: The First Line of Treatment
For most women with stage 3 ovarian cancer, treatment begins with surgery. The goal is to remove as much visible cancer as possible, a procedure called debulking or cytoreductive surgery. Surgeons aim to leave behind no individual tumor deposit larger than 1 cm, which qualifies as “optimal debulking.” Achieving this target makes the chemotherapy that follows significantly more effective, because smaller remaining deposits are more vulnerable to the drugs.
The extent of surgery varies depending on where the cancer has spread. It typically includes removing both ovaries and fallopian tubes, the uterus, the omentum (the fatty tissue draped over the intestines, where ovarian cancer commonly spreads), and any other visible disease on the abdominal lining. In some cases, portions of the bowel, spleen, or diaphragm lining need to be removed as well. This is major surgery, and recovery typically takes several weeks before chemotherapy can begin.
When imaging suggests the cancer is too widespread for surgery to achieve optimal results upfront, doctors may recommend starting with chemotherapy first (called neoadjuvant chemotherapy) to shrink the tumors, followed by surgery after a few cycles.
Chemotherapy After Surgery
Platinum-based chemotherapy is the standard treatment after surgery for all women with stage 3 disease. The most common regimen pairs a platinum drug (carboplatin) with a taxane drug (paclitaxel), given intravenously every three weeks. Depending on the specific protocol, treatment typically runs for six to eight cycles, meaning roughly four to six months of active chemotherapy.
Some treatment centers use a dose-dense schedule, where paclitaxel is given weekly at a lower dose instead of every three weeks at a higher dose. Clinical trials, including a large Japanese study, showed that this dose-dense approach improved survival in certain patient populations, though it can cause more side effects like low blood counts and nerve-related symptoms in the hands and feet.
The side effects of platinum-taxane chemotherapy include fatigue, nausea, hair loss, numbness or tingling in the fingers and toes (peripheral neuropathy), and increased susceptibility to infections due to lowered white blood cell counts. Most of these effects are temporary, though neuropathy can linger for months after treatment ends.
Maintenance Therapy and Genetic Testing
One of the most significant advances in ovarian cancer treatment is maintenance therapy, which is given after chemotherapy to help keep the cancer from returning. A class of drugs called PARP inhibitors has changed the outlook for many women with stage 3 disease, particularly those whose tumors carry mutations in the BRCA1 or BRCA2 genes.
These mutations impair a cell’s ability to repair its own DNA. PARP inhibitors exploit that weakness by blocking a second DNA repair pathway, effectively trapping cancer cells in a state where they cannot fix themselves and die. In a landmark trial published in the New England Journal of Medicine, women with advanced ovarian cancer and BRCA mutations who took the PARP inhibitor olaparib as maintenance therapy after responding to platinum chemotherapy had substantially longer periods before their cancer progressed compared to those who did not.
Because of these results, genetic testing for BRCA and other DNA repair mutations (sometimes grouped under a broader category called homologous recombination deficiency, or HRD) is now a routine part of ovarian cancer care. Your tumor’s genetic profile directly affects which maintenance therapies you are eligible for and can significantly influence your long-term outcome. PARP inhibitors are taken as daily pills, often for two years or longer, and their most common side effects include nausea, fatigue, and lowered blood counts.
Survival Rates and Recurrence
Five-year survival for stage 3 ovarian cancer depends heavily on how far the disease has spread. SEER data from the National Cancer Institute reports a five-year relative survival of 70.7% for regional-stage disease (cancer confined to the pelvis and nearby structures) and 31.8% for distant-stage disease (cancer that has spread more widely through the abdomen). Most stage 3 cases fall into the distant category, though women with 3A1 disease (lymph node-only spread) tend to have better outcomes than those with extensive peritoneal involvement.
These numbers represent averages across all patients and do not account for individual factors that strongly influence prognosis: age, overall health, whether surgery achieved optimal debulking, how the cancer responds to chemotherapy, and tumor genetics. Women with BRCA mutations, for example, tend to respond better to platinum chemotherapy and are eligible for PARP inhibitor maintenance, both of which improve survival.
Recurrence is common in stage 3 ovarian cancer. Between 70% and 90% of women will experience a return of the disease after completing initial treatment. Recurrence does not mean treatment has failed permanently. Many women undergo additional rounds of chemotherapy, sometimes combined with surgery, and can achieve remissions lasting months or years. The pattern of ovarian cancer, for many women, becomes one of repeated treatment and remission cycles rather than a single course of therapy. Maintenance therapies like PARP inhibitors are specifically designed to extend those remission periods as long as possible.